Imugene’s CF33, or Vaxinia, is a modified DNA virus of the Poxviridae family developed by Professor Yuman Fong at the City of Hope Comprehensive Cancer Center in Los Angeles. Vaccinia, or pox, viruses have a track record of safe use in millions of humans, as the original variant was the active constituent of the vaccine that eradicated smallpox, and first proved able to kill cancer cells in 1922. CF33 has the potential to act as both a gene therapy delivery vehicle and an oncolytic (cancer-killing) agent.

Read More